Analytical Data
-
Gene name
NRTN
- Application
-
Alternative Names
NRTN；Neurturin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99748
-
Expression Region
96-197aa
-
AA Sequence
ARLGARPCGL RELEVRVSEL GLGYASDETV LFRYCAGACE AAARVYDLGL RRLRQRRRLR RERVRAQPCC RPTAYEDEVS FLDAHSRYHT VHELSARECA CV
-
Molecular Weight
23.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NRTN (Neurturin) is a member of the GDNF (Glial cell line-Derived Neurotrophic Factor) family, which plays a crucial role in neuronal survival and differentiation. The interest in NRTN recombinant protein arises from its potential therapeutic applications in neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Research has shown that NRTN supports the survival of dopaminergic neurons and promotes the regeneration of damaged neural tissues, making it a promising candidate for neuroprotective strategies. Furthermore, NRTN interacts with specific receptors, leading to downstream signaling pathways that enhance neuronal resilience and function. Over the years, advances in recombinant DNA technology have facilitated the production of NRTN in various systems, such as bacteria and mammalian cells, allowing for detailed characterization and assessment of its biological properties. Studies have demonstrated that the application of NRTN recombinant protein can improve motor function in animal models of neurodegeneration, sparking interest in its potential use as a therapeutic agent. Consequently, ongoing research aims to elucidate the mechanisms underlying NRTN's neuroprotective effects and to evaluate its efficacy in clinical settings, reinforcing the significance of understanding neurotrophic factors in the context of neurobiology and therapeutic development.
